Literature DB >> 19901432

Human papillomavirus infection (HPV) & screening strategies for cervical cancer.

Ashok Sehgal1, Veena Singh.   

Abstract

The incidence of cervical cancer is declining slowly necessitating concerted and organized control measures. Control through primary prevention has become a distinct reality though a prophylactic vaccine, which may take quite some time for its widespread use. Thus control of cervical cancer through secondary preventive measures is the only viable solution now. While high quality cytology screening may not be feasible for widescale implementation in developing countries because of lack of necessary infrastructure, quality control and poor sensitivity of cytology, alternative screening modalities such as visual screening techniques and HPV-DNA can be explored. Some technical and feasibility aspects of these three modalities are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19901432

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  4 in total

1.  Detection of human papillomavirus in women attending Pap cervical screening camp at a peripheral hospital of North-Eastern India.

Authors:  Sibnarayan Datta; Manisha Agarwal; Soumya Chatterjee; Hemanta Kumar Gogoi; Vijay Veer; Lokendra Singh
Journal:  Med J Armed Forces India       Date:  2013-08-05

Review 2.  Epidemiology of cervical cancer with special focus on India.

Authors:  Aswathy Sreedevi; Reshma Javed; Avani Dinesh
Journal:  Int J Womens Health       Date:  2015-04-16

3.  Perception of human papillomavirus infection, cervical cancer and HPV vaccination in North Indian population.

Authors:  Showket Hussain; Vilas Nasare; Malasha Kumari; Shashi Sharma; Mohammad Aijaz Khan; Bhudev C Das; Mausumi Bharadwaj
Journal:  PLoS One       Date:  2014-11-11       Impact factor: 3.240

4.  Modelling risk assessment for cervical cancer in symptomatic Saudi women.

Authors:  Wedad Al-Madani; Anwar E Ahmed; Haitham Arabi; Sumaiah Al Khodairy; Nashmia Al Mutairi; Abdul Rahman Jazieh
Journal:  Saudi Med J       Date:  2019-05       Impact factor: 1.484

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.